Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

Completed · Phase 2

Conditions studied: Pancreatic Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of gemcitabine with or without CI-994 in treating patients who have advanced pancreatic cancer.

Key facts

Study ID

NCT00004861

Run by

Pfizer

Starts

1999-10-01

Expected to finish

2001-09-01

Last updated by the study team

2012-08-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cedars-Sinai Comprehensive Cancer Center — Los Angeles, California, United States
• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Sinai Hospital of Baltimore — Baltimore, Maryland, United States
• William Beaumont Hospital — Royal Oak, Michigan, United States
• Raleigh Hematology/Oncology Associates - Wake Practice — Raleigh, North Carolina, United States
• Jewish Hospital of Cincinnati, Inc. — Cincinnati, Ohio, United States
• Ireland Cancer Center — Cleveland, Ohio, United States
• West Clinic, P.C. — Memphis, Tennessee, United States
• Sarah Cannon-Minnie Pearl Cancer Center — Nashville, Tennessee, United States
• Tyler Cancer Center — Tyler, Texas, United States
• Northern Virginia Oncology Group — Fairfax, Virginia, United States
• St. Boniface General Hospital — Winnipeg, Manitoba, Canada
• Nova Scotia Cancer Centre — Halifax, Nova Scotia, Canada
• Cancer Care Ontario-London Regional Cancer Centre — London, Ontario, Canada
• Ottawa Regional Cancer Center - General Division — Ottawa, Ontario, Canada
• Centre Hospitalier de l'Universite de Montreal — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.